Signal events: Cell signal transduction and its inhibition in cancer.
暂无分享,去创建一个
[1] A. Adjei,et al. Blocking oncogenic Ras signaling for cancer therapy. , 2001, Journal of the National Cancer Institute.
[2] D. Alessi,et al. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. , 1999, The Biochemical journal.
[3] D. Lane. The promise of molecular oncology , 1998, The Lancet.
[4] D. Stern,et al. Specificity within the EGF family/ErbB receptor family signaling network , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.
[5] Monilola A. Olayioye,et al. The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.
[6] A. Boral,et al. Translational research: walking the bridge between idea and cure--seventeenth Bruce F. Cain Memorial Award lecture. , 1998, Cancer research.
[7] E. Rowinsky. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Downward. Mechanisms and consequences of activation of protein kinase B/Akt. , 1998, Current opinion in cell biology.
[9] J. Mendelsohn. Targeting the epidermal growth factor receptor for cancer therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Walker. The erbB/HER type 1 tyrosine kinase receptor family , 1998, The Journal of pathology.
[11] G. Mills,et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. , 1997, Cancer research.
[12] E. Eisenhauer,et al. Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] R. Herbst,et al. The role of the epidermal growth factor receptor in the treatment of colorectal carcinoma. , 2002, Seminars in oncology nursing.
[14] K. Gibson,et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. , 2002, Cancer research.
[15] Christine C. Hudson,et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. , 2000, Cancer research.
[16] R. Schwall,et al. Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. , 2002, Cancer research.
[17] D. Lynch,et al. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. , 2002, Seminars in oncology.
[18] J. Sarkaria,et al. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. , 1998, Cancer research.
[19] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[20] D. Birnbaum,et al. ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor , 2000, Nature Cell Biology.
[21] J. Blenis,et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[22] A. Harris,et al. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? , 1999, Journal of the National Cancer Institute.
[23] Joe W. Gray,et al. PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.
[24] Lewis C Cantley,et al. The phosphoinositide 3-kinase pathway. , 2002, Science.
[25] J. Baselga,et al. Mechanism of action of anti-HER2 monoclonal antibodies. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] H. Kim,et al. Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. , 1994, The Journal of biological chemistry.
[27] H. Scher,et al. A potential role for activated HER-2 in prostate cancer. , 2000, Seminars in oncology.
[28] Bert Vogelstein,et al. Combinatorial chemoprevention of intestinal neoplasia , 2000, Nature Medicine.
[29] M. Hidalgo,et al. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy , 2000, Oncogene.
[30] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[31] A. Adjei,et al. Novel targets for lung cancer therapy: part I. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Y. Yarden,et al. Signal transduction: Molecular ticket to enter cells , 2002, Nature.
[33] Daniel,et al. There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. , 1998 .
[34] Yosef Yarden,et al. ErbB Receptors and EGF-like Ligands: Cell Lineage Determination and Oncogenesis Through Combinatorial Signaling , 1997, Journal of Mammary Gland Biology and Neoplasia.
[35] Susan M. Chang,et al. 33 Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma , 2003 .
[36] R. Pazdur,et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] S. Wilhelm,et al. BAY 43-9006: preclinical data. , 2002, Current pharmaceutical design.
[38] Y. Yarden,et al. The role of ubiquitylation in signaling by growth factors: implications to cancer. , 2003, Seminars in cancer biology.
[39] A. Citri,et al. Drug‐induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy , 2002, The EMBO journal.
[40] B. Riedl,et al. Design and discovery of small molecules targeting raf-1 kinase. , 2002, Current pharmaceutical design.
[41] P. Houghton,et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. , 1998, Molecular pharmacology.
[42] R. Roth,et al. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[43] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[44] Kohjiro Ueki,et al. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone , 1997, Nature.
[45] M. Simon,et al. Receptor Tyrosine Kinases Specific Outcomes from General Signals , 2000, Cell.
[46] R. Daly,et al. Take your partners, please--signal diversification by the erbB family of receptor tyrosine kinases. , 1999, Growth factors.
[47] Carlos L Arteaga,et al. ErbB-targeted therapeutic approaches in human cancer. , 2003, Experimental cell research.
[48] V. Yong,et al. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. , 1999, European journal of biochemistry.
[49] D. Bigner,et al. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). , 1997, The Biochemical journal.